Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013471 | 0.85 | KMT2A (0.67) | KMT2AMEN1MGLLCYP3A4NPSR1 | |
| SCHEMBL19715895 | 0.84 | KMT2A (0.55) | KMT2AMEN1MGLLNR2E1NPSR1 | |
| SCHEMBL23033352 | 0.80 | ALDH1A1 (0.52) | KMT2AMEN1MGLLCYP3A4CYP3A5 | |
| SCHEMBL5688541 | 0.79 | CACNA2D1 (0.60) | KMT2AMEN1MGLLCYP3A4CYP3A5 | |
| SCHEMBL6797094 | 0.79 | KMT2A (0.58) | KMT2AMEN1MGLLCYP3A4NPSR1 | |
| SCHEMBL23033355 | 0.78 | KMT2A (0.48) | KMT2AMEN1MGLLCYP3A4CYP3A5 | |
| SCHEMBL8115616 | 0.76 | CYP2D6 (0.57) | KMT2AMEN1MGLLGLSMAPT | |
| SCHEMBL3805489 | 0.76 | CYP2D6 (0.57) | KMT2AMEN1MGLLGLSMAPT | |
| SCHEMBL15093706 | 0.76 | CYP3A4 (0.71) | KMT2AMEN1MGLLCYP3A4CYP3A5 | |
| SCHEMBL31071488 | 0.76 | CYP3A4 (0.71) | KMT2AMEN1MGLLCYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-01-29 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| EP-3233830-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096126-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, SIGMAR1 | KMT2A 2653/4885MEN1 4744/4885MGLL 1937/4885 |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | KMT2A 2653/4885MEN1 4744/4885MGLL 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.